UBE2K

Across TCGA pan-cancer cohorts, UBE2K RNA is linked to patient survival in 25 of 34 cancer types, making it the most broadly survival-associated UBE2K data layer compared with 1 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher UBE2K RNA is associated with worse overall survival. In most high-consensus cancer types, elevated UBE2K expression acts as an unfavorable survival marker, although some lineages such as COAD and UCS show a favorable association.

LIHC, UVM, and KICH are the cancer types where UBE2K RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.701	0.847	<.001	80	view →
UVM	DFS	Quartile	III,IV	0.170	0.832	<.001	73	view →
KICH	DFS	Quartile	III,IV	0.146	1.000	.002	50	view →
PAAD	OS	Tertile	II,III,IV	0.401	0.737	.001	50	view →
COAD	OS	Tertile	III,IV	0.813	0.372	.004	47	view →
LUAD	OS	Quartile	All	0.230	0.444	<.001	34	view →
CESC	OS	Quartile	IV	0.305	0.789	.022	30	view →
ACC	DFS	Quartile	All	0.374	0.757	.015	25	view →
UCS	DFS	Tertile	IV	0.936	0.364	.024	24	view →
KIRC	DFS	Tertile	All	0.843	0.703	.007	22	view →
SKCM	DFS	Quartile	All	0.737	0.509	<.001	20	view →
HNSC	DFS	Quartile	All	0.543	0.771	.005	19	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 25 lineages.

UBE2K–LIHC (OS)

Open the LIHC breakdown →